Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Villanueva A, Longo DL. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Guo Y, Ren Y, Chen L, et al. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer. 2022;22(1):270. doi:10.1186/s12885-022-09325-6
   PubMed Web of Science ®Google Scholar
• Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–399. doi:10.3322/caac.21161
   PubMed Web of Science ®Google Scholar
• Zaitoun MMA, Elsayed SB, Zaitoun NA, et al. Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3-<5 cm.. Int J Hyperthermia. 2021;38(1):248–256. doi:10.1080/02656736.2021.1887941
   PubMed Web of Science ®Google Scholar
• Shi Q, Wang F, Du N, et al. Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: a retrospective study. Clin Res Hepatol Gastroenterol. 2022;46(7):101986. doi:10.1016/j.clinre.2022.101986
   PubMed Web of Science ®Google Scholar
• Keshavarz P, Raman SS. Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Abdom Radiol. 2022;47(3):1009–1023. doi:10.1007/s00261-021-03368-2
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960–974. doi:10.1016/j.jhep.2021.07.004
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Rimini M, Kudo M, et al. Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. Liver Cancer. 2022;11(6):527–539. doi:10.1159/000525145
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Li Q, Han J, Yang Y, et al. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961. doi:10.3389/fimmu.2022.1070961
   PubMedGoogle Scholar
• Sperandio RC, Pestana RC, Miyamura BV, et al. Hepatocellular Carcinoma Immunotherapy. Annu Rev Med. 2022;73(1):267–278. doi:10.1146/annurev-med-042220-021121
   PubMed Web of Science ®Google Scholar
• Yau T, Park J-W, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: a Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Singal AG, Kudo M, Bruix J. Breakthroughs in Hepatocellular Carcinoma Therapies. Clin Gastroenterol Hepatol. 2023;21(8):2135–2149. doi:10.1016/j.cgh.2023.01.039
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Hatzidakis A, Müller L, Krokidis M, et al. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers. 2022;14(10):2469. doi:10.3390/cancers14102469
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang J, Jiang J, et al. CTLA-4 Blockade Suppresses Progression of Residual Tumors and Improves Survival After Insufficient Radiofrequency Ablation in a Subcutaneous Murine Hepatoma Model. Cardiovasc Intervent Radiol. 2020;43(9):1353–1361. doi:10.1007/s00270-020-02505-6
   PubMed Web of Science ®Google Scholar
• Ma X-L, Shen M-N, Hu B, et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol. 2019;12(1):37. doi:10.1186/s13045-019-0724-7
   PubMed Web of Science ®Google Scholar
• Kang TW, Lim HK, Cha DI. Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. Clin Mol Hepatol. 2017;23(1):95–101. doi:10.3350/cmh.2017.0006
   PubMed Web of Science ®Google Scholar
• Han J-W, Yoon S-K. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: possible Roles of Adjuvant Immunotherapy. Pharmaceutics. 2021;13(9):1387. doi:10.3390/pharmaceutics13091387
   PubMed Web of Science ®Google Scholar
• Duan X, Wang M, Han X, et al. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice. Cell Cycle. 2020;19(24):3595–3607. doi:10.1080/15384101.2020.1853942
   PubMed Web of Science ®Google Scholar
• Shi Q, Zhou X, Zhang Z, et al. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. Front Immunol. 2022;13:1097625. doi:10.3389/fimmu.2022.1097625
   PubMed Web of Science ®Google Scholar
• Yin L, Liu K-C, Lv W-F, et al. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study. Cancer Imaging. 2023;23(1):52. doi:10.1186/s40644-023-00574-7
   PubMed Web of Science ®Google Scholar
• Yuan Y, He W, Yang Z, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023;109(5):1222–1230. doi:10.1097/JS9.0000000000000256
   PubMed Web of Science ®Google Scholar
• Xin Y, Zhang X, Liu N, et al. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma. Hepatol Int. 2023;17(3):753–764. doi:10.1007/s12072-023-10502-3
   PubMed Web of Science ®Google Scholar
• Zhu H-D, Li H-L, Huang M-S, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58. doi:10.1038/s41392-022-01235-0
   PubMed Web of Science ®Google Scholar
• Stefanini B, Ielasi L, Chen R, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–291. doi:10.1080/14737140.2023.2181162
   PubMed Web of Science ®Google Scholar
• Li S-Q, Yang Y, Ye L-S. Angiogenesis and immune checkpoint dual blockade: opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol. 2022;28(42):6034–6044. doi:10.3748/wjg.v28.i42.6034
   PubMed Web of Science ®Google Scholar
• Bannangkoon K, Hongsakul K, Tubtawee T. Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization. Cancer Imaging. 2023;23(1):51. doi:10.1186/s40644-023-00575-6
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Fu Y, Peng W, Zhang W, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol. 2023;58(4):413–424. doi:10.1007/s00535-023-01976-x
   PubMed Web of Science ®Google Scholar
• Jácome AA, Castro ACG, Vasconcelos JPS, et al. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: a Meta-analysis. JAMA Netw Open. 2021;4(12):e2136128. doi:10.1001/jamanetworkopen.2021.36128
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang M, Zhu J, et al. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother. 2020;132:110797. doi:10.1016/j.biopha.2020.110797
   PubMed Web of Science ®Google Scholar